Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbance

Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbance - Phase II study of elental for chemotherapy induced mucositis oral and nutritional disturbance

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009298

Enrollment

Registered

2012-11-09

Start date

2012-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer chemotherapy induced mucositis oral and nutritional disturbance

Interventions

elental

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)having cancer chemotherapy induced oral mucosits 2)Performance status(ECOG) 0 or 1 3)age 20 years over 4)life expetancy > 3months 5)adequate organ function 6)written informed consent

Exclusion criteria

Exclusion criteria: 1)severe symptom with cancer 2)difficult to take elental due to other gastro intestinal symptoms 3)recieve other treatment for oral mucositis 4)physician judged inadequate

Design outcomes

Primary

Measure	Time frame
response rate of oral mucositis	—

Secondary

Measure	Time frame
persistency of elental efficacy for nutrition change of body weight change of oral intake safety	—

Countries

Japan

Contacts

Public Contactmasato nakamura

Aizawa Hospital Aizawa comprehensive cancer center

geka-dr7@ai-hosp.or.jp0263-33-8600

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026